hat
Syantis yo moun yo sanble menm ki genyen batay yon gwo pwoblèm nan kèk ansyen jèn terapi tras, effets kote jèn inséré a te malfezan "sou objektif", y metòd pou chanje sou kansè pwomouvwa gènes. Déjà, gen kèk moun ki te fè jèn Terapi pou lòt kondisyon yo kenbe tèt, tankou SCID (bulle pour iminitè), y ' al dèyè sou devlope leucémie kòm yon bò effet tretman. "Pwoblèm lan te genyen yo yo gen pou vire sou kote lòt gènes sans, y gènes kansè,"a Des.
eng
The scientists appear to have overcome a significant problem in some previous gene therapy trials, where the inserted gene had harmful “off target” effects, including switching on cancer-promoting genes. Previously, some children given gene therapy for other immune conditions, such as SCID (bubble baby syndrome), have gone on to develop leukaemia as a side-effect of the treatment. “The problem was they tended to turn on other genes indiscriminately, including cancer genes,” said Thrasher.